



## Start Here for FILSPARI (sparsentan) Prior Authorizations

**96%** of commercially insured patients have access to FILSPARI, and a prior authorization (PA) is likely required

### Gather the following clinical information when you're ready to submit the PA:

- ☐ Individual is 18 years or older
- ☐ Diagnosis of primary IgAN (kidney biopsy, if available)
- ☐ Prior use or intolerance of corticosteroid
- ☐ Proteinuria (g/g or g/day) and eGFR
- ☐ History of failure of an **ACEi/ARB** or trial for 3 months. Some examples of ACEi/ARB:
  - **ACEis tend to end in “-pril”:** benazepril, enalapril, lisinopril<sup>1</sup>
  - **ARBs tend to end in “-tan”:** losartan, irbesartan, valsartan<sup>2</sup>

### What you can expect with the PA process:

A PA means that your office **must submit clinical information** before FILSPARI is approved for your patient.

- Your office can **submit a PA electronically** through the Traverre TotalCare® electronic PA (ePA) system, or fax it to the insurance plan
- The insurance plan will review the PA and **make a coverage decision**
- If a PA is denied, which may be due to missing required information, your Traverre Access & Reimbursement Manager can help avoid an additional delay in treatment

▶ **Two PAs may be required for 200 mg initiation and 400 mg maintenance dosing**

Visit [TraverreTotalCare.com](https://www.TraverreTotalCare.com) for more information and downloadable access resources.

## The Traverse TotalCare® ePA process



**Complete the FILSPARI Patient Start Form.** To receive the ePA login information, include the email address and/or fax number for your office staff who handle PA support.



**A patient-specific PIN** for the login to the ePA system will be sent to your staff member via email and/or fax.



**Using the PIN, complete and submit the ePA,** including required documentation, in the portal.

**Have all documentation on hand when you are ready to submit.** The Traverse TotalCare® ePA system will guide you through questions and the documentation upload.

**Reach out to your Access & Reimbursement Manager when you're ready to start your ePA submission for support**

**You can count on Traverse TotalCare® for assistance with coordinating patient access to treatment with FILSPARI® (sparsentan).**

Call **1-833-345-7727**, Monday-Friday 8 AM-8 PM ET or visit us online.

ePA, electronic prior authorization; PA, prior authorization.

**References:** 1. Mayo Clinic. Angiotensin-converting enzyme (ACE) inhibitors. Updated August 16, 2023. Accessed October 8, 2024. <https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/in-depth/ace-inhibitors/art-20047480> 2. Mayo Clinic. Angiotensin II receptor blockers. Updated August 4, 2023. Accessed October 8, 2024. <https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/in-depth/angiotensin-ii-receptor-blockers/art-20045009>